ARTICLES
Newsletter | MedTechnique Consulting November 2020
Read our end of year newsletter for 2020 to learn about: As 2020 draws to close businesses and organisations are reflecting on the many changes and challenges that they have faced this year. The healthcare industry is no different and we have all had to adapt....
New MSAC Guidelines and the implications for applicants.
To successfully diffuse a new medical technology and procedure into the desirable Australian market, an application to the Medical Services Advisory Committee (MSAC) is required in most cases. This is to attain a Medical Benefits Schedule (MBS) item number so that...
Free Webinar: 6th Annual Drugs & Devices Australia – Reimbursement Update.
Please join us for this free webinar, hosted by Sarah Griffin, Director of MedTechnique Consulting and George Papadopoulos Partner & Director of Lucid Health Consulting as they discuss the latest developments in gaining reimbursement in the Australian market. George and Sarah share their insights into the complex world of drug and device reimbursement applications and strategy in the Australian market, as well as answering webinar attendee’s questions.
Our Newsletter | MedTechnique Consulting July 2020.
Read our mid-year newsletter of 2020 to learn about: This year has certainly been challenging in many ways for most countries, governments’, the health care industry, and individuals. We hope that you, your families, and businesses are faring well. As...
What’s the impact of COVID-19 on Medical Device Sales and Reimbursement in Australia?
Impact of COVID-19 on Medical Device Sales and Reimbursement in Australia Australia has been very fortunate in that it has avoided the worst of the pandemic. There have been 7500 cases in Australia of whom the vast majority have recovered with a total of 104 deaths. ...
BiotechTalks – AusBiotech’s new virtual event series.
MedTechnique Consulting to host webcast discussing Health Economics, Reimbursement and why it is important.
Experts in medical device reimbursement and market access in Australia